Zura Bio Limited (Nasdaq: ZURA)

Zura Bio Limited (Nasdaq: ZURA)

Zura Bio Limited, trading as ZURA on Nasdaq, is a clinical-stage biotechnology company striving to develop innovative medications for immune and inflammatory disorders. The company's current focus lies in progressing three assets, namely tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168, all of which have completed phase 1/1b studies and are deemed Phase 2 ready. Zura Bio's objective is to showcase the efficacy, safety, and dosing convenience of these assets across a range of therapeutic indications for immune and inflammatory disorders. Headquartered in Henderson, NV, Zura Bio's operations span across the UK and the USA.

Established in 2022, Zura Bio operates within the biopharma and biotechnology industries, garnering significant attention from investors. Notably, the company recently secured an $80.00M Post-IPO Equity investment on 27 April 2023. This funding round was led by Deep Track Capital, Suvretta Capital Management, and Great Point Partners.